公开(公告)号：US20200347020A1

公开(公告)日：2020-11-05

申请号：US16935565

申请日：2020-07-22

Applicant: Merck Sharp & Dohme Corp.

Inventor： Gregory L. Adams ,  Jason M. Cox ,  John S. Debenham ,  Scott Edmondson ,  Eric J. Gilbert ,  Yan Guo ,  Yu Jiang ,  Hubert Josien ,  Hyunjin M. Kim ,  Ping Lan ,  Shouwu Miao ,  Christopher W. Plummer ,  Murali Rajagopalan ,  Unmesh Shah ,  Zhongxiang Sun ,  Quang T. Truong ,  Feroze Ujjainwalla ,  Francisco Velazquez ,  Srikanth Venkatraman ,  Takao Suzuki ,  Nengxue Wang

IPC: C07D217/04 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D417/12 ,  C07D417/14 ,  C07D401/06 ,  C07D417/04 ,  A61K31/4725 ,  C07D417/06 ,  C07D217/22 ,  A61K45/06 ,  A61K31/472 ,  A61K9/48 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P29/00

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

公开(公告)号：US20190161448A1

公开(公告)日：2019-05-30

申请号：US16096710

申请日：2017-05-19

Applicant: Merck Sharp & Dohme Corp.

Inventor： Gregory L. Adams ,  Jason M. Cox ,  John S. Debenham ,  Scott Edmondson ,  Eric J. Gilbert ,  Yan Guo ,  Yu Jiang ,  Hubert Josien ,  Hyunjin M. Kim ,  Ping Lan ,  Shouwu Miao ,  Christopher W. Plummer ,  Murali Rajagopalan ,  Unmesh Shah ,  Zhongxiang Sun ,  Quang T. Truong ,  Feroze Ujjainwalla ,  Francisco Velazquez ,  Srikanth Venkatraman ,  Takao Suzuki ,  Nengxue Wang

IPC: C07D217/04 ,  C07D401/12 ,  C07D401/04 ,  C07D401/06 ,  C07D417/04 ,  C07D417/14 ,  C07D417/12 ,  C07D413/04 ,  A61P3/10 ,  A61P3/06 ,  A61P3/04 ,  A61P29/00

Abstract: The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

公开(公告)号：US11161819B2

公开(公告)日：2021-11-02

申请号：US16935565

申请日：2020-07-22

Applicant: Merck Sharp & Dohme Corp.

Inventor： Gregory L. Adams ,  Jason M. Cox ,  John S. Debenham ,  Scott Edmondson ,  Eric J. Gilbert ,  Yan Guo ,  Yu Jiang ,  Hubert Josien ,  Hyunjin M. Kim ,  Ping Lan ,  Shouwu Miao ,  Christopher W. Plummer ,  Murali Rajagopalan ,  Unmesh Shah ,  Zhongxiang Sun ,  Quang T. Truong ,  Feroze Ujjainwalla ,  Francisco Velazquez ,  Srikanth Venkatraman ,  Takao Suzuki ,  Nengxue Wang

IPC: C07D217/04 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D417/12 ,  C07D417/14 ,  C07D401/06 ,  C07D417/04 ,  A61K31/4725 ,  C07D417/06 ,  C07D217/22 ,  A61K45/06 ,  A61K31/472 ,  A61K9/48 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P29/00

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.